14 Sep

G1 Therapeutics Posted 242.59% Returns Year-to-Date

WRITTEN BY Margaret Patrick

G1 Therapeutics stock movements

G1 Therapeutics (GTHX), a clinical-stage company, has risen 242.59% YTD (year-to-date), mainly due to its three important oncology research programs achieving major milestones. It was led by its most advanced clinical program for investigational first-in-class, short-acting, intravenously-administered cyclin-dependent kinase 4/6 (or CDK 4/6) inhibitor trilaciclib in the first half of 2018.

The consensus recommendation for G1 Therapeutics over the next 12 months is a “buy.” Of the six analysts covering the company in September, two have recommended a “strong buy,” and four have recommended a “buy.”

Wall Street analysts have projected a 12-month consensus target price for G1 Therapeutics of $67, which would be a decline of 1.43% over its closing price on September 13.

G1 Therapeutics Posted 242.59% Returns Year-to-DateThe above chart highlights the key milestone events that could impact G1 Therapeutics stock in the future.

Growth drivers

G1 Therapeutics is targeting the myelopreservation market, worth more than $7 billion, with trilaciclib, which is currently being evaluated in multiple Phase 2 trials. The drug is being tested as a backbone therapy in combination regimens in first-line, second-line, and third-line small cell lung cancer, as well as in metastatic triple-negative breast cancers. All these indications are hard to treat, and the company thus expects to benefit from significant unmet demand in those areas.

It’s also targeting the oral CDK4/6 market, worth more than $20 billion, with investigational CDK4/6 inhibitor lerociclib. G1 It’s also targeting the selective estrogen receptor degrader (or SERD) market in the ER+ (estrogen-receptor-positive) breast cancer segment, which is worth more than $1 billion.

As of June 30, G1 Therapeutics had $188.2 million in cash on its balance sheet.

In the next part, we’ll look at the growth trends for Sarepta Therapeutics.

Latest articles

After opening on a bearish note on Wednesday, Tesla (TSLA) was trading with 4.8% losses for the day, near $195.25 at 1:16 PM ET.

With voting conducted in seven phases panning six weeks, India’s (EPI) elections have been a grand affair—to say the least. Tomorrow is the day of the results.

Qualcomm (QCOM) stock fell more than 10% in the first half of trading on May 22 after it lost its licensing lawsuit with the US FTC (Federal Trade Commission).

Apple (AAPL) suffered a setback recently when the US Supreme Court allowed an antitrust lawsuit against the company to proceed.

Today doesn’t seem to be a good day for electric vehicle companies. Earlier today, NIO stock hit an all-time low of $4.00.

22 May

Cannabis Stocks Struggle to Find Direction

WRITTEN BY Adam Jones

The cannabis sector has been struggling to find direction on May 22, with cannabis stocks trading on a largely mixed note in the first half.

172.31.38.64